<DOC>
	<DOC>NCT00300885</DOC>
	<brief_summary>A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.</brief_summary>
	<brief_title>A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Stage IIIB (with effusion) or Stage IV NSCLC any histology No prior chemotherapy Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 Greater than or equal to 18 years of age Life expectancy at least 12 weeks Adequate bone marrow, liver and renal function Prior systemic anti cancer therapy Known brain metastasis. Patients with neurological symptoms should undergo at computed tomography (CT) scan/magnetic resonance imaging (MRI) of the brain to exclude brain metastasis Pulmonary hemorrhage/bleeding event &gt; Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 within 4 weeks of first dose of study drug Thrombotic or embolic events including Transient ischemic attack (TIA) within the past 6 months Uncontrolled hypertension Any other hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 weeks of first dose of study drug Major surgery within 4 weeks Evidence or history of bleeding diathesis or coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>